Global Eating Disorders Markets, 2017-2018 & 2019-2026: Edgemont's Fluoxetine Tablets and Takeda's Vyvanse are the Only FDA-Approved Drugs

DUBLIN, June 24, 2019 /PRNewswire/ -- The "Market Spotlight: Eating Disorders" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Takeaways

• Worldwide, the report estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
• The author forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026. Edgemont's fluoxetine tablets and Takeda's Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
• There are only three industry-sponsored drugs in active clinical development for eating disorders, with two drugs in Phase II and one in Phase III.
• Therapies in mid-to-late-stage development for eating disorders focus on targets such as dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, and ghrelin receptor. These drugs are administered via the subcutaneous, oral, and intranasal routes.
• The only high-impact upcoming event in the eating disorders space is topline Phase II trial results for OPNT001. The overall likelihood of approval of a Phase I psychiatry-other asset is 11.4%, and the average probability a drug advances from Phase III is 80.8%. Drugs, on average, take 9.2 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.
• There have been only three licensing and asset acquisition deals involving eating disorders drugs during 2014-19. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for eating disorders have been in the late phase of development, with 91% of trials in Phase III, and only 9% in Phase II.
• The US has a substantial lead in the number of eating disorders clinical trials globally, while Germany leads the major EU markets.
• Clinical trial activity in the eating disorders space is dominated by completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with four trials.
• Takeda leads industry sponsors with the highest number of clinical trials for eating disorders.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
Psychotherapy
Medications

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
Dasotraline for Eating Disorders (July 25, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY
Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/yppi1x

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets